hr+/her2- metastatic breast cancer

Release time ：Dec-12,2024

Hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer is a prevalent form of breast cancer that typically responds well to endocrine therapy. However, once the disease has metastasized, the complexity of treatment escalates and the prognosis worsens.

The primary treatment for patients with HR positive/HER2 negative metastatic breast cancer is endocrine therapy, which may include selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). For some patients, additional drug therapies such as CDK4/6 inhibitors might be combined to enhance treatment efficacy. Physicians tailor treatment plans based on individual patient factors including disease status, age, and overall health.

Patients with HR positive/HER2 negative metastatic breast cancer are advised to maintain a healthy lifestyle, including a balanced diet, regular exercise, and emotional well-being to boost their physical resilience and resistance. Regular follow-ups are crucial to monitor disease progression closely, and any unusual symptoms should prompt immediate medical consultation. Medication adherence is critical; patients must take their prescribed medications as directed, without altering the dosage or stopping treatment without medical guidance to ensure treatment effectiveness.